Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
DYAX > SEC Filings for DYAX > Form 8-K on 27-Jun-2013All Recent SEC Filings

Show all filings for DYAX CORP

Form 8-K for DYAX CORP


27-Jun-2013

Regulation FD Disclosure


Item 7.01. Regulation FD Disclosure.

On June 25, 2013, Dyax Corp. ("Dyax") filed an Investigational New Drug application ("IND") with the U.S. Food and Drug Administration ("FDA") to allow clinical testing of DX-2930, Dyax's fully human monoclonal antibody inhibitor of plasma kallikrein. Subject to review and comment by the FDA on the IND, clinical testing of DX-2930 can commence 30 days following the IND filing. If the FDA does not comment on the IND within 30 days after filing, Dyax intends to commence a Phase 1 trial to evaluate the safety, tolerability and pharmacokinetics of DX-2930 in healthy volunteers.

The information in this Current Report on Form 8-K shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Act"), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Act, except to the extent that Dyax specifically incorporates it by reference.

Certain information included in this current report is forward-looking in nature within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. This report uses terminology such as "believes," "plans," "expects," "intends" and similar expressions to identify forward-looking statements. Examples of forward-looking statements in this report include statements about our intention to commence a Phase I trial of DX-2930. The forward-looking statements in this report are based on our current good faith beliefs; however, actual results may differ due to inaccurate assumptions regarding our ability to initiate, or hire a third party to initiate, such trial in a timely manner. Consequently, we cannot guarantee that any of the forward-looking statements will prove to be accurate. The forward-looking statements in this report speak only as of the date of this report.


  Add DYAX to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for DYAX - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.